Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727228 | 1.00 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31670673 | 1.00 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL3740743 | 1.00 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL30871986 | 1.00 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL800074 | 1.00 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL14596379 | 0.91 | KMT2A (0.55) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL18251809 | 0.89 | KMT2A (0.58) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL12461580 | 0.88 | KMT2A (0.57) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL31379237 | 0.87 | KMT2A (0.55) | KMT2ACASP3EPHX2MDM4TP53 | |
| SCHEMBL17175116 | 0.87 | KMT2A (0.61) | KMT2ACASP3EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051912-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR INHIBITORS | SANOFI (FR) | 2025-03-13 | — | — | WO | disclosed |
| CN-109248323-B | Acylated GLP-1 derivatives | 杭州先为达生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| US-11274135-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-03-15 | — | — | US | disclosed |
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| EP-2820038-B1 | GLP-1 PRODRUGS | NOVO NORDISK AS (DK) | 2020-06-17 | — | — | EP | disclosed |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2020-04-23 | — | — | US | disclosed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
| US-10308700-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2019-06-04 | — | — | US | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030064921-A1 | Methods and compounds for modulating melanocortin receptor ligand binding and activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-03 | — | — | US | disclosed |
| WO-2001085930-A9 | METHODS AND COMPOUNDS FOR MODULATING MELANOCORTIN RECEPTOR LIGAND BINDING AND ACTIVITY | UNIV CALIFORNIA (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001085930-A2 | METHODS AND COMPOUNDS FOR MODULATING MELANOCORTIN RECEPTOR LIGAND BINDING AND ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-15 | — | — | WO | disclosed |
| US-20010018511-A1 | Anticancer agent | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2001-08-30 | — | — | US | disclosed |
| EP-0958305-A2 | INHIBITIONS OF THE INTERACTION BETWEEN P53 AND MDM2 | Novartis AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999054321-A1 | SUBSTITUTED DIAMINES AND THEIR USE AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| WO-1998001467-A2 | INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 | NOVARTIS AG (CH) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064921-A1 | Methods and compounds for modulating melanocortin receptor ligand binding and activity | MC3R, MC4R, MC1R | KMT2A 2717/4885CASP3 4601/4885EPHX2 3880/4885 |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | KMT2A 313/4885CASP3 1822/4885EPHX2 1351/4885 |
| US-10308700-B2 | GLP-1 derivatives | GLP1R, GIPR, GCG | KMT2A 870/4885CASP3 827/4885EPHX2 2589/4885 |
| US-11274135-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | KMT2A 189/4885CASP3 1511/4885EPHX2 1623/4885 |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | KMT2A 313/4885CASP3 1822/4885EPHX2 1351/4885 |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | KMT2A 313/4885CASP3 1822/4885EPHX2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.